Global Biological Product Manufacturing Market Size, Status and Forecast 2019-2025

The biological product manufacturing is a complex process which produces products derived from recombinant DNA technology to develop a series of processes to manufacture therapeutic products. A biological product can be a virus, antitoxin, vaccine, blood component or derivative, allergenic product, or analogous product, or any therapeutic serum used for the treatment of a disease in humans. These biological products were developed from multicellular systems comprising of plants, animals, unicellular organisms and a mammalian cell. Biological products are composed of sugars, nucleic acids or combination of both.
The biological products are produced in three ways: by developing ways to achieve commercial production of the substance to be used, by gene alteration of the molecule and finally by developing an entirely new substance. Some of the tools used by modern day researcher in the manufacturing of biological products are recombinant DNA and monoclonal antibodies. Recombinant DNA involves altering of the DNA chain of one organism with desired DNA molecule to produce a novel biological product. Monoclonal antibodies were developed from single cell cultures using cloning techniques; these were designed to fight against toxins, viruses, and cancer cells. The first genetically engineered biological product approved for use in the U.S. was a vaccine for hepatitis-B which was approved in 1986, in the same year, other biological products like therapeutic monoclonal antibodies (MAB’s) and alpha interferon’s were approved.
However, the major restraining factors for biological product manufacturing market are the high cost of manufacturing of biological products, high level of price competition amongst competitors and efficacy and reliability of the biological product.
In 2018, the global Biological Product Manufacturing market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Biological Product Manufacturing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Biological Product Manufacturing development in United States, Europe and China.

The key players covered in this study
Novartis
F.Hoffmann-La Roche
Merck
Bayer
Lonza
China Biologic Products
Pfizer
Sanofi
Teva Pharmaceutical Industries
Amgen

Market segment by Type, the product can be split into
Monoclonal Antibodies
Recombinant Proteins
Growth Hormones
Beta Interferon
Therapeutic Enzymes

Market segment by Application, split into
Hospitals
Specialized Clinics
Government Research Institutes

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Biological Product Manufacturing status, future forecast, growth opportunity, key market and key players.
To present the Biological Product Manufacturing development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Biological Product Manufacturing are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.